Premium
Treatment of D arier disease with oral alitretinoin
Author(s) -
Letulé V.,
Herzinger T.,
Ruzicka T.,
Molin S.
Publication year - 2013
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/ced.12078
Subject(s) - acitretin , dermatology , medicine , isotretinoin , retinoid , darier's disease , refractory (planetary science) , genodermatosis , tretinoin , disease , psoriasis , retinoic acid , acne , biochemistry , chemistry , physics , astrobiology , gene
Summary Darier disease ( DD ) is an autosomal dominant skin disease. Treatment is often difficult and unsatisfactory because of the chronic nature of the condition and the irritant potential of various therapeutic agents. Systemic vitamin A derivatives such as acitretin and isotretinoin are the treatment of choice, but their use is often limited by class‐specific side‐effects. Alitretinoin (9‐ cis ‐retinoic acid), has antiproliferative and anti‐inflammatory potential, and is licensed for the systemic treatment of chronic hand eczema in a number of countries. Unlike acitretin, alitrenoin requires contraception in women of childbearing age to be extended for only 1 month after the end of treatment. There is evidence that alitretinoin might be a well‐tolerated alternative for the systemic treatment of various retinoid‐responsive skin diseases. We present two cases of women with refractory DD successfully treated with alitretinoin without marked side‐effects, who both obtained near‐complete remission of their skin lesions.